Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

45 results about "Chemoattractant receptors" patented technology

Chemoattractant receptors are a family of G protein coupled seven transmembrane cell surface receptors (GPCRs). According to their source of ligands and expression patterns, the family members are categorized into classical GPCRs and chemokine GPCRs.

3-Aminocyclopentanecarboxamides as modulators of chemokine receptors

The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and / or activity.
Owner:INCYTE HLDG CORP

CXCR4 chemokine receptor binding compounds

ActiveUS7291631B2Inhibit HIV replicationDestroy effectivenessBiocideOrganic chemistryProgenitorCXCR4
The present invention relates to compounds that bind to chemokine receptors, and having the formulawherein each A, X, Y, R1, R2 and R3 are substituents. The present invention also relates to methods of using such compounds, such as in treating HIV infection and inflammatory conditions such as rheumatoid arthritis. Furthermore, the present invention relates to methods to elevate progenitor and stem cell counts, as well as methods to elevate white blood cell counts, using such compounds.
Owner:GENZYME CORP

Method of screening for modulators of HIV infection

The present invention provides polynucleotides that encode the chemokine receptors 88-2B or 88C and materials and methods for the recombinant production of these two chemokine receptors. Also provided are assays utilizing the polynucleotides which facilitate the identification of ligands and modulators of the chemokine receptors. Receptor fragments, ligands, modulators, and antibodies are useful in the detection and treatment of disease states associated with the chemokine receptors such as atherosclerosis, rheumatoid arthritis, tumor growth suppression, asthma, viral infection, AIDS, and other inflammatory conditions.
Owner:OGEDA SA

3-Aminocyclopentanecarboxamides as Modulators of Chemokine Receptors

The present invention is directed to compounds of Formula I: I which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and / or activity.
Owner:INCYTE

Chemokine receptor binding heterocyclic compounds with enhanced efficacy

ActiveUS7550484B2Increase the number ofDestroy effectivenessBiocideOrganic chemistryProgenitorChemokine receptor D6
Compounds that interact with the CXCR4 receptor are described. These compounds are useful in treating, for Example, HIV infection and inflammatory conditions such as rheumatoid arthritis, as well as asthma or cancer, and are useful in methods to elevate progenitor and stem cell counts as well as methods to elevate white blood cell counts.
Owner:GENZYME CORP

Cyclopentyl modulators of chemokine receptor activity

Cyclopentyl compounds of Formula (I) are modulators of chemokine receptor activity: wherein D, G, R2, R3 and R8 in Formula (I) are defined herein. The compounds, and pharmaceutically acceptable salts and individual diastereomers thereof, are useful in the treatment and prevention of HIV infection, in delaying the onset of AIDS, and in the treatment of AIDS. The compounds are also useful for treating other diseases and conditions mediated by chemokine receptors.
Owner:MERCK SHARP & DOHME CORP

PGD2 receptor antagonists for the treatment of inflammatory diseases

Disclosed herein are compounds represented by Structural Formula (I): (I), wherein the variables are defined herein. Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2 (“CRTH2”) for the treatment of inflammatory disorders.
Owner:MILLENNIUM PHARMA INC

Oxo-imidazolidines as modulators of chemokine receptors

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
Owner:CHEMOCENTRYX INC

Pyrimidine derivatives useful for the treatment of diseases mediated by crth2

InactiveUS20070129355A1Excellent CRTH antagonistic activityBiocideSenses disorderSinusitisMammal
The present invention relates to a pyrimidine derivative of the formula (I) and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The pyrimidine derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals; and inflammatory diseases characterized by T lymphocytes and profuse leukocyte infiltrates such as psoriasis, eczema, inflammatory bowel disease, ulcerative colitis, Crohn's disease, COPD (chronic obstructive pulmonary disorder) and arthritis.
Owner:GB007 INC

Chimeric chemokines receptors capable of making T cells tend to tumor locations

ActiveCN103965362AEfficient arrivalOvercome the problem of not being able to effectively reach the tumor sitePeptide/protein ingredientsGenetic material ingredientsHigh concentrationImmunologic function
The invention belongs to the fields of molecular biology and immunology, and relates to chimeric chemokines receptors capable of making T cells tend to tumor locations. Specifically, the chimeric chemokines receptors are formed in a manner that a peptide fragment of a generated factor secreted by efficiently-combined tumor cells or tumor stromal cells is connected with a transmembrane region originated from a high-affinity receptor and a signal domain peptide fragment capable of making the T cells efficiently migrated through hinge structures. A membrane outer peptide fragment receives a corresponding factor signal and transfers the signal into cells, and a related path for promoting T cell chemotaxis is started through an intracellular region of the signal domain peptide fragment capable of promoting the migration of the T cells, so that the T cells modified by the chimeric chemokines receptors have a characteristic of migrating to the corresponding factor high concentration direction, and a normal tumor killing activity is not weaken, so as to ensure the tumor adoptive cell therapy effector T cells can efficiently reach the tumor nidus locations, and play a role in treatment.
Owner:SHANGHAI CELL THERAPY GRP CO LTD

Chemokine receptor binding polypeptides

The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
Owner:ABLYNX NV

Chemokine receptor antagonists as therapeutic agents

The present invention provides methods and compositions to reduce immune tolerance at specific sites. In one aspect, the present invention comprises methods and compositions to reduce tumorigenicity. In an embodiment, the present invention reduces recruitment of tolerance-inducing antigen presenting cells (APCs) or their precursors to a tumor and / or tumor draining lymph node by decreasing binding of at least one tumor-associated ligand to a chemokine receptor present on the tolerance-inducing APCs or APC precursors. In an embodiment, the chemokine receptor is CCR6 and the tumor-associated ligand is mip-3α. In another aspect, the present invention comprises methods and compositions to reduce immune tolerance to a virus. In an embodiment, the virus is HIV. The present invention further provides for the development of CCR6 antibodies and antagonists as therapeutic agents to prevent or reduce immune tolerance.
Owner:GEORGIA HEALTH SCI UNIV RES INST

3-aminocyclopentanecrboxamides as modulators of chemokine receptors

The present invention is directed to compounds of Formula I:which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and / or activity.
Owner:INCYTE HLDG CORP

3-aminocyclopentanecarboxamides as modulators of chemokine receptors

The present invention is directed to compounds of Formula I:which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and / or activity.
Owner:INCYTE HLDG CORP

Active polypeptide with function of antagonizing chemokine receptor CXCR4 as well as design preparation and biomedical application of active polypeptide

ActiveCN104892744AImprove binding efficiencyRole of the strong anti-chemokine receptor CXCR4Peptide/protein ingredientsAntiviralsDiseaseMyeloid leukemia
The invention discloses an active polypeptide designed to have a natural chemotactic factor N-end region. The active polypeptide inhibits HIV-1 from invading and infecting cells by antagonizing the activity of the chemokine receptor. The invention further discloses a design method for the active polypeptide. According to molecular dynamic simulation, an appropriate connecting bridge is designed for connecting two polypeptide fragments, so that the polypeptide synthesis sequence is determined, the polypeptide is synthesized in a solid-phase mode, and finally the biologic activity of the active polypeptide is tested. The active polypeptide disclosed by the invention can be used as a CXCR4 receptor antagonist, a precursor medicine for treating AIDS and a stem cell mobilizer, and is used for treating acute myeloid leukemia and various CXCR4-associated diseases.
Owner:徐岩 +1

Chemokine receptor binding polypeptides

The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
Owner:ABLYNX NV

3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors

The present invention relates to 3-cycloalkylaminopyrrolidine derivatives of the formula 1: (wherein R<1>, R<2>, R<3>, R<4>, R<5>, R<6>, R<7>, X, Y and Z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the CCR2 and / or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and / or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and / or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.
Owner:INCYTE

N-substituted heterocyclic amines as modulators of chemokine receptor activity

The present application describes modulators of chemokine receptors of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
Owner:BRISTOL MYERS SQUIBB CO

Cell fusion assays using fluorescence resonance energy transfer

InactiveUS7029868B2Prevent and ameliorate effect of HIV-Compound screeningApoptosis detectionChemokine receptorDisease injury
Methods of identifying inhibitors of the fusion of two types of cells, particularly when fusion is mediated by the interaction of a viral protein and such cellular proteins as CD4 and chemokine receptors, are disclosed. The methods are suitable for identifying substances that are useful for the treatment and prevention of viral diseases. Particularly preferred methods are useful for the identification of inhibitors of HIV-1 infection.
Owner:MERCK & CO INC

Method of treating allergen induced airway disease

The invention features methods of treating allergic asthma by administering to a subject a chimeric polypeptide that comprises a first polypeptide domain comprising at least one moiety that specifically binds to a chemokine receptor; and, a second polypeptide domain comprising at least one of (a)-(d): (a) a moiety that binds to a T cell surface polypeptide, (b) a moiety that binds to a dendritic cell surface polypeptide, (c) a moiety that binds to a cell toxin, and (d) a cell toxin.
Owner:MICROMET AG

Imidazo 1,2-c pyrimidinylacetic acid derivatives

The present invention relates to an imidazo[1,2-c]pyrimidinylacetic acid derivative and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The imidazo[1,2-c]pyrimidinylacetic acid derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals; and inflammatory diseases characterized by T lymphocytes and profuse leukocyte infiltrates such as psoriasis, eczema, inflammatory bowel disease, ulcerative colitis, Crohn's disease, COPD (chronic obstructive pulmonary disorder) and arthritis.
Owner:ACTIMIS PHARM INC

Chemokine receptor binding compounds

The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
Owner:GENZYME CORP

Neural regeneration peptides and uses therefor

This invention relates to neural regeneration peptides (NRPs), including NRP-2945, NRP-2983 and NNZ-4921, as well as the receptors that have been newly identified as interacting with these NRPs, such as CXCR4 in collaboration with CCR3. The invention further relates to methods of using these NRPs and its respective chemokine receptors, as well as compositions comprising such components.
Owner:CURONZ HLDG

Treating cancer

A method for treating cancer comprising applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor, optionally the chemokine receptor CCR7, CCR5, CCR6, CCR8, CXCR4, CXCR7, CCR4, CCR9, CCR10, CXCR3 or CXCR5 or to a Treg receptor immobilized directly or indirectly on the support thus removing one or more chemokine receptor, optionally CCR7, CCR5, CCR6, CCR8, CXCR4, CXCR7, CCR4, CCR9, CCR10, CXCR3 or CXCR5 or Treg receptor expressing cells from the peripheral blood of the patient or subject. Various companion diagnostic methods and useful binding reagents are also described.
Owner:TLA TARGETED IMMUNOTHERAPIES AB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products